CA2002182C - Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi - Google Patents
Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi Download PDFInfo
- Publication number
- CA2002182C CA2002182C CA 2002182 CA2002182A CA2002182C CA 2002182 C CA2002182 C CA 2002182C CA 2002182 CA2002182 CA 2002182 CA 2002182 A CA2002182 A CA 2002182A CA 2002182 C CA2002182 C CA 2002182C
- Authority
- CA
- Canada
- Prior art keywords
- serotonin
- drug
- drugs
- fenfluramine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 208000011580 syndromic disease Diseases 0.000 title claims description 5
- 238000000034 method Methods 0.000 title abstract description 4
- 230000029849 luteinization Effects 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 114
- 229940079593 drug Drugs 0.000 claims abstract description 110
- 230000036651 mood Effects 0.000 claims abstract description 32
- 206010036618 Premenstrual syndrome Diseases 0.000 claims abstract description 30
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims abstract description 25
- 235000019789 appetite Nutrition 0.000 claims abstract description 24
- 230000036528 appetite Effects 0.000 claims abstract description 24
- 229960004597 dexfenfluramine Drugs 0.000 claims abstract description 24
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims abstract description 20
- 229960002464 fluoxetine Drugs 0.000 claims abstract description 20
- 230000002295 serotoninergic effect Effects 0.000 claims abstract description 19
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 119
- 229940076279 serotonin Drugs 0.000 claims description 58
- 210000004556 brain Anatomy 0.000 claims description 22
- -1 cyanimipramine Chemical compound 0.000 claims description 22
- 230000005062 synaptic transmission Effects 0.000 claims description 17
- 230000001404 mediated effect Effects 0.000 claims description 16
- 210000000225 synapse Anatomy 0.000 claims description 16
- LXOHMGALVZOYRF-BTJKTKAUSA-N (z)-but-2-enedioic acid;6-nitro-2-piperazin-1-ylquinoline Chemical compound OC(=O)\C=C/C(O)=O.C1=CC2=CC([N+](=O)[O-])=CC=C2N=C1N1CCNCC1 LXOHMGALVZOYRF-BTJKTKAUSA-N 0.000 claims description 12
- DBGIVFWFUFKIQN-SECBINFHSA-N Levofenfluramine Chemical compound CCN[C@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-SECBINFHSA-N 0.000 claims description 12
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 12
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 12
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 11
- ASNYPHGOFQAGQM-VQIMIIECSA-N (5r,7r)-n,n-dimethyl-5-(4-nitrophenoxy)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-7-amine Chemical compound O([C@H]1C2=CC=CC=C2CC[C@H](C1)N(C)C)C1=CC=C([N+]([O-])=O)C=C1 ASNYPHGOFQAGQM-VQIMIIECSA-N 0.000 claims description 11
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 11
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 11
- RVSGRNKUJJUAPV-UHFFFAOYSA-N benzo[d][1,2]benzoxazepine Chemical compound O1N=CC2=CC=CC=C2C2=CC=CC=C12 RVSGRNKUJJUAPV-UHFFFAOYSA-N 0.000 claims description 11
- LQXYCDLHSKICDY-UHFFFAOYSA-N cianopramine Chemical compound C1CC2=CC=C(C#N)C=C2N(CCCN(C)C)C2=CC=CC=C21 LQXYCDLHSKICDY-UHFFFAOYSA-N 0.000 claims description 11
- 229950001408 cianopramine Drugs 0.000 claims description 11
- 229960001653 citalopram Drugs 0.000 claims description 11
- 229960005426 doxepin Drugs 0.000 claims description 11
- OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 claims description 11
- 229950003930 femoxetine Drugs 0.000 claims description 11
- 229960004038 fluvoxamine Drugs 0.000 claims description 11
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 11
- 229960004801 imipramine Drugs 0.000 claims description 11
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 11
- LWRJZIPAGMGXQJ-DIJVWCDGSA-N org-6582 Chemical compound Cl.C1C2=CC(Cl)=CC=C2[C@@H]2[C@@H](N)[C@H]1C=CC2 LWRJZIPAGMGXQJ-DIJVWCDGSA-N 0.000 claims description 11
- 229960002296 paroxetine Drugs 0.000 claims description 11
- 229960003991 trazodone Drugs 0.000 claims description 11
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 11
- 229960002431 trimipramine Drugs 0.000 claims description 11
- 229960002791 zimeldine Drugs 0.000 claims description 11
- OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 claims description 11
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 10
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 10
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 claims description 9
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 claims description 9
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims description 9
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 9
- 229960004606 clomipramine Drugs 0.000 claims description 9
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims description 9
- 229960001140 cyproheptadine Drugs 0.000 claims description 9
- WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 claims description 9
- 229960004650 metergoline Drugs 0.000 claims description 9
- 229960001186 methysergide Drugs 0.000 claims description 9
- 229960002601 protriptyline Drugs 0.000 claims description 9
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 9
- 230000000697 serotonin reuptake Effects 0.000 claims description 9
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 8
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 8
- 229960004644 moclobemide Drugs 0.000 claims description 8
- 230000001242 postsynaptic effect Effects 0.000 claims description 8
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 7
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 7
- WZXHSWVDAYOFPE-UHFFFAOYSA-N brofaromine Chemical compound C=1C2=CC(OC)=CC(Br)=C2OC=1C1CCNCC1 WZXHSWVDAYOFPE-UHFFFAOYSA-N 0.000 claims description 7
- 229950004068 brofaromine Drugs 0.000 claims description 7
- 229910052744 lithium Inorganic materials 0.000 claims description 7
- 229960001158 nortriptyline Drugs 0.000 claims description 7
- 229960000964 phenelzine Drugs 0.000 claims description 7
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 7
- 229960000624 procarbazine Drugs 0.000 claims description 7
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 7
- 229960003741 tranylcypromine Drugs 0.000 claims description 7
- CJAWPFJGFFNXQI-UHFFFAOYSA-N 2-chloro-6-(1-piperazinyl)pyrazine Chemical compound ClC1=CN=CC(N2CCNCC2)=N1 CJAWPFJGFFNXQI-UHFFFAOYSA-N 0.000 claims description 5
- XRXDAJYKGWNHTQ-UHFFFAOYSA-N quipazine Chemical compound C1CNCCN1C1=CC=C(C=CC=C2)C2=N1 XRXDAJYKGWNHTQ-UHFFFAOYSA-N 0.000 claims description 5
- 229950002315 quipazine Drugs 0.000 claims description 5
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 4
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- OWOHLURDBZHNGG-YFKPBYRVSA-N (8ar)-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1CNC(=O)[C@@H]2CCCN12 OWOHLURDBZHNGG-YFKPBYRVSA-N 0.000 claims 10
- 229960000836 amitriptyline Drugs 0.000 claims 10
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 10
- SADQVAVFGNTEOD-UHFFFAOYSA-N indalpine Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 claims 10
- 229950002473 indalpine Drugs 0.000 claims 8
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 claims 6
- 229960001625 furazolidone Drugs 0.000 claims 6
- 230000003518 presynaptic effect Effects 0.000 claims 6
- 230000005764 inhibitory process Effects 0.000 claims 4
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 claims 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 claims 2
- 230000009534 synaptic inhibition Effects 0.000 claims 2
- 150000001540 azides Chemical class 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 13
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000005906 menstruation Effects 0.000 description 8
- 230000003821 menstrual periods Effects 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 206010056465 Food craving Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 206010012374 Depressed mood Diseases 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- BKPRVQDIOGQWTG-ICOOEGOYSA-N [(1s,2r)-2-phenylcyclopropyl]azanium;[(1r,2s)-2-phenylcyclopropyl]azanium;sulfate Chemical compound [O-]S([O-])(=O)=O.[NH3+][C@H]1C[C@@H]1C1=CC=CC=C1.[NH3+][C@@H]1C[C@H]1C1=CC=CC=C1 BKPRVQDIOGQWTG-ICOOEGOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 description 2
- 206010021654 increased appetite Diseases 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 208000012672 seasonal affective disease Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000952 serotonin receptor agonist Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- GGDBEAVVGFNWIA-UHFFFAOYSA-N 6-nitro-2-(1-piperazinyl)quinoline Chemical compound C1=CC2=CC([N+](=O)[O-])=CC=C2N=C1N1CCNCC1 GGDBEAVVGFNWIA-UHFFFAOYSA-N 0.000 description 1
- 101100020619 Arabidopsis thaliana LATE gene Proteins 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- SHAYBENGXDALFF-UHFFFAOYSA-N Nortriptyline hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2C(=CCC[NH2+]C)C2=CC=CC=C21 SHAYBENGXDALFF-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- RXBKMJIPNDOHFR-UHFFFAOYSA-N Phenelzine sulfate Chemical compound OS(O)(=O)=O.NNCCC1=CC=CC=C1 RXBKMJIPNDOHFR-UHFFFAOYSA-N 0.000 description 1
- 102000004659 Presynaptic Receptors Human genes 0.000 description 1
- 108010003717 Presynaptic Receptors Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 206010043268 Tension Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229960005119 amitriptyline hydrochloride Drugs 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- 230000000578 anorexic effect Effects 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940011681 elavil Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 229960002102 imipramine hydrochloride Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940110127 marplan Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940087524 nardil Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003039 nortriptyline hydrochloride Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940087824 parnate Drugs 0.000 description 1
- 229960004790 phenelzine sulfate Drugs 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000000484 premenstrual tension Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- OGQDIIKRQRZXJH-UHFFFAOYSA-N protriptyline hydrochloride Chemical compound [Cl-].C1=CC2=CC=CC=C2C(CCC[NH2+]C)C2=CC=CC=C21 OGQDIIKRQRZXJH-UHFFFAOYSA-N 0.000 description 1
- 229960001509 protriptyline hydrochloride Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- XFOHHIYSRDUSCX-UHFFFAOYSA-M sodium;5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidin-3-ide-2,4-dione Chemical compound [Na+].C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)[N-]C1=O XFOHHIYSRDUSCX-UHFFFAOYSA-M 0.000 description 1
- 229940118176 surmontil Drugs 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 229940041597 tofranil Drugs 0.000 description 1
- 108010021724 tonin Proteins 0.000 description 1
- 229960003797 tranylcypromine sulfate Drugs 0.000 description 1
- 229960002301 trazodone hydrochloride Drugs 0.000 description 1
- OHHDIOKRWWOXMT-UHFFFAOYSA-N trazodone hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 OHHDIOKRWWOXMT-UHFFFAOYSA-N 0.000 description 1
- YDGHCKHAXOUQOS-BTJKTKAUSA-N trimipramine maleate Chemical compound [O-]C(=O)\C=C/C([O-])=O.C1CC2=CC=CC=C2[NH+](CC(C[NH+](C)C)C)C2=CC=CC=C21 YDGHCKHAXOUQOS-BTJKTKAUSA-N 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 229940045977 vivactil Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2002182 CA2002182C (fr) | 1989-11-03 | 1989-11-03 | Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2002182 CA2002182C (fr) | 1989-11-03 | 1989-11-03 | Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2002182A1 CA2002182A1 (fr) | 1991-05-03 |
| CA2002182C true CA2002182C (fr) | 2000-06-13 |
Family
ID=4143458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2002182 Expired - Fee Related CA2002182C (fr) | 1989-11-03 | 1989-11-03 | Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2002182C (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759346B2 (en) | 2005-12-16 | 2014-06-24 | Novartis Ag | Organic compounds |
| US8933090B2 (en) | 2004-06-18 | 2015-01-13 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
| US9012451B2 (en) | 2002-09-04 | 2015-04-21 | Novartis Ag | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists |
| US9657010B2 (en) | 2004-07-14 | 2017-05-23 | Novartis Ag | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators |
| EP3976013A4 (fr) * | 2019-05-31 | 2023-05-31 | Alyra Biotech Pty Ltd | Procédés, compositions et dispositifs pour traiter des états neuroinflammatoires |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
-
1989
- 1989-11-03 CA CA 2002182 patent/CA2002182C/fr not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9012451B2 (en) | 2002-09-04 | 2015-04-21 | Novartis Ag | Aza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists |
| US9567343B2 (en) | 2002-09-04 | 2017-02-14 | Novartis Ag | Aza-bicyloalkyl ethers and their use as alpha7-nachr agonists |
| US9849117B2 (en) | 2002-09-04 | 2017-12-26 | Novartis Ag | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
| US8933090B2 (en) | 2004-06-18 | 2015-01-13 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
| US9475811B2 (en) | 2004-06-18 | 2016-10-25 | Novartis Ag | 1-aza-bicyclo[3.3.1]nonanes |
| US9657010B2 (en) | 2004-07-14 | 2017-05-23 | Novartis Ag | Substituted quinuclidines as alpha 7-nicotinic acetylcholine receptor activity modulators |
| US8759346B2 (en) | 2005-12-16 | 2014-06-24 | Novartis Ag | Organic compounds |
| US9206181B2 (en) | 2005-12-16 | 2015-12-08 | Novartis Ag | 1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders |
| EP3976013A4 (fr) * | 2019-05-31 | 2023-05-31 | Alyra Biotech Pty Ltd | Procédés, compositions et dispositifs pour traiter des états neuroinflammatoires |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2002182A1 (fr) | 1991-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weiser et al. | The pharmacologic approach to the treatment of obesity | |
| US5708035A (en) | Methods of use and compositions of R(-) fluoxetine | |
| CA2126305C (fr) | Traitements au moyen de venlafaxine | |
| EP0386117B1 (fr) | Traitement du syndrome de phase luteale tardive ou premenstruelle | |
| US5502080A (en) | Combined use of dopamine and serotonin agonists in the treatment of allergic disorders | |
| US4971998A (en) | Methods for treating the premenstrual or late luteal phase syndrome | |
| US8481599B2 (en) | Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism | |
| EA011094B1 (ru) | Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения | |
| JP5491475B2 (ja) | ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置 | |
| JP2019522666A (ja) | ２型糖尿病の治療のためのアドレナリン受容体アゴニストの併用 | |
| CA2002182C (fr) | Compositions pour le traitement du syndrome premenstruel ou de la phase luteinique tardive, et leur mode d'emploi | |
| US5223540A (en) | Method for treating the premenstrual or late luteal phase syndrome | |
| EP0792649A1 (fr) | Traitement de l'insomnie | |
| IE912826A1 (en) | Method for treating the premenstrual or late luteal phase¹syndrome | |
| IE84082B1 (en) | Method for treating the premenstrual or late luteal phase syndrome | |
| US20050009927A1 (en) | Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors | |
| CA2591315C (fr) | Methode pour le traitement de la depression et des troubles d'humeur depressifs | |
| WO2005023265A1 (fr) | Association d'inhibiteurs de recaptage de la serotonine et d'inhibiteurs de recaptage de la noradrenaline | |
| TW574037B (en) | Nicotine addiction treatment | |
| Bolo | The Biological Basis of Bulimia | |
| MXPA00010945A (en) | New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |